Novartis Vaccines and Diagnostics, Inc. v. Hoffman-La Roche Inc.

597 F. Supp. 2d 706, 2009 U.S. Dist. LEXIS 14656, 2009 WL 349760
CourtDistrict Court, E.D. Texas
DecidedFebruary 3, 2009
Docket6:07-cv-00507
StatusPublished
Cited by1 cases

This text of 597 F. Supp. 2d 706 (Novartis Vaccines and Diagnostics, Inc. v. Hoffman-La Roche Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Novartis Vaccines and Diagnostics, Inc. v. Hoffman-La Roche Inc., 597 F. Supp. 2d 706, 2009 U.S. Dist. LEXIS 14656, 2009 WL 349760 (E.D. Tex. 2009).

Opinion

ORDER

DAVID FOLSOM, District Judge.

Before the Court is Defendants’ Renewed Motion to Transfer Pursuant to 28 U.S.C §§ 1404 & 1406, or, in the alternative, to Dismiss Defendant Trimeris. Dkt. Nos. 60 & 61. Also before the Court are Plaintiffs response, Defendants’ reply, Plaintiffs sur-reply, Plaintiffs Supplemental Brief, and Defendants’ Supplemental Brief. Dkt. Nos. 66, 70, 71, 86, and 87. The Court held a hearing on this and other matters on December 9, 2008. Dkt. No. 76 (hearing transcript). Having considered all relevant papers and pleadings, the Court finds that Defendants’ motions should be DENIED.

I. BACKGROUND

Plaintiff Novartis Vaccines and Diagnostics, Inc. (“Novartis”) filed this patent infringement action on November 19, 2007. Dkt. No. 1. Novartis alleges that Defendants infringe U.S. Patent No. 7,285,271 (“the '271 Patent”) entitled “Antigenic composition comprising an HIV gag or env polypeptide,” by making and commercializing a drug known as Fuzeon. Fuzeon is a HIV inhibitor that was developed in North Carolina by scientists at Defendant Trim-eris, Inc. (“Trimeris”). The active pharmaceutical ingredient for Fuzeon is manufactured by Defendant Roche Colorado at its Colorado facilities. This active ingredient must be processed further by Hoffman-La Roche Inc. (“Hoffman La-Roche”) in Michigan or by F. Hoffman-La Roche Ltd. (“Roche Ltd.”) in Switzerland. The drug is then packaged by Hoffman La-Roche in New Jersey before it is marketed nationwide through Hoffman La-Roche’s wholly-owned subsidiary, Roche Laboratories, Inc. (“Roche Labs”).

Defendants Hoffman-La Roche, Roche Labs, and Trimeris previously requested that this case be transferred from the Eastern District of Texas to the Eastern District of North Carolina. Dkt. No. 29. Because the Fifth Circuit’s en banc opinion in In re Volkswagen of America, Inc., 545 F.3d 304 (5th Cir.2008), was still pending, this Court dismissed Defendants’ motion to transfer without prejudice to refiling. Dkt. No. 51. Since that time, the Fifth Circuit has released its Volkswagen decision and the Federal Circuit has applied the regional circuit’s precedent to patent law in In re TS Tech USA Corp., 551 F.3d 1315 (Fed.Cir.2008). Defendants now renew their motion to transfer in light of these recent decisions. Dkt. No. 60. If transfer is denied, Trimeris moves, in the alternative, for dismissal under Rules 12(b)(2) and (3). Dkt. No. 61.

II. MOTION TO TRANSFER

A. Legal Principles

Section 1404(a) provides: “For the convenience of parties and witnesses, in the interest of justice, a district court may transfer any civil action to any other district or division where it might have been brought.” 28 U.S.C. § 1404(a). Section 1404(a) presupposes that the action has been brought in a proper venue but authorizes its transfer to another proper district that is more suited to the convenience of witnesses and the needs of justice. The Supreme Court has noted that § 1404(a) is intended to place discretion in the district court to adjudicate motions to transfer according to an “individualized, case-by-case consideration of convenience and fairness.” *710 Stewart Org., Inc. v. Ricoh Corp., 487 U.S. 22, 29, 108 S.Ct. 2239, 101 L.Ed.2d 22 (1988); Van Dusen v. Barrack, 376 U.S. 612, 622, 84 S.Ct. 805, 11 L.Ed.2d 945 (1964).

This Court generally recognizes a plaintiffs right to choose a venue and will not disturb that choice absent a showing that convenience and fairness necessitate transfer under the facts of that particularized case. In re Triton, 70 F.Supp.2d 678, 688 (E.D.Tex.1999). Accordingly, the defendant has the burden to show “good cause” that transfer is appropriate. In re Volkswagen, 545 F.3d at 314 (“[I]n order to support its claim for a transfer, [defendant] must satisfy the statutory requirement and clearly demonstrate that a transfer is for the convenience of parties and witnesses, in the interest of justice.” (emphasis added)).

The Fifth Circuit has made clear that the first determination a district court must make is whether the claims might have been brought in the suggested transferee district. Id. at 312-13. After such a determination, the district court must then consider the convenience of the parties in both venues. Id. at 314-16; see also J2 Global Commc’ns, Inc. v. Protus IP Solutions, Inc., Civil Action No. 6:08-CV-275, 2008 WL 5378010, at *3-6 (E.D.Tex. Dec. 23, 2008) (J. Love). A convenience determination is essentially a balancing of the inconveniences that will transpire as a result of the plaintiffs choice of venue.

This balancing of conveniences involves the examination of several private and public interest factors, none of which has dispositive weight. In re Volkswagen, 545 F.3d at 315. The private factors address (1) the availability of sources of proof, (2) the court’s ability to secure witnesses’ attendance, (3) the expense associated with witnesses’ attendance, and (4) all other factors relevant in conducting an expeditious and inexpensive trial. Id. (citing Gulf Oil Corp. v. Gilbert, 330 U.S. 501, 67 S.Ct. 839, 91 L.Ed. 1055(1947)). The public convenience factors address (1) administrative issues and the congestion of the courts’ dockets, (2) the local interest in having the dispute decided locally, (3) the courts’ familiarity with the controlling law, and (4) the potential conflicts of law issues that may arise. Id.

B. Parties’ Positions and Discussion

The initial inquiry in resolving a motion to transfer venue under § 1404(a) is whether the district court to which the movant requests transfer is a district in which the case could have been initially filed. In re Volkswagen, 545 F.3d at 312-13. The parties do not contest that venue would have been proper had this case been brought in the Eastern District of North Carolina because all Defendants are subject to personal jurisdiction therein. See Dkt. No. 60 at 11. The Court now moves to the second stage of the analysis, which considers the private and public interest factors restated in In re Volkswagen.

1. Private Convenience Factors

a. Availability of Sources of Proof

Defendants argue that the “key sources of proof with regard to defendants’ lack of enablement defenses reside in North Carolina, where the invention and pre-clinical development of Fuzeon occurred.” Dkt. No. 60 at 13.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
597 F. Supp. 2d 706, 2009 U.S. Dist. LEXIS 14656, 2009 WL 349760, Counsel Stack Legal Research, https://law.counselstack.com/opinion/novartis-vaccines-and-diagnostics-inc-v-hoffman-la-roche-inc-txed-2009.